Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Y-Mabs Therapeutics (YMAB – Research Report) today and set a price target of $12.00. The company’s shares closed last Friday at $8.99.
Stranahan covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Y-Mabs Therapeutics, and Novavax. According to TipRanks, Stranahan has an average return of -8.4% and a 50.00% success rate on recommended stocks.
Y-Mabs Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.17.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $20.48 and a one-year low of $2.70. Currently, Y-Mabs Therapeutics has an average volume of 758.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Read More on YMAB:
- Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
- YMAB Earnings this Week: How Will it Perform?
- Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
- Y-mAbs Therapeutics announces presentation of naxitamab data at AACR
- Y-mAbs Therapeutics announces first patient dosed in Phase 1 trial of GD2-SADA
